Log In
BCIQ
Print this Print this
 

STP-206, STP206

  Manage Alerts
Collapse Summary General Information
Company Sigma-Tau Group
DescriptionBiotherapeutic comprising live Lactobacillus acidophilus and Bifidobacterium animalis subspecies lactis
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase I/II
Standard IndicationColitis
Indication DetailsPrevent necrotizing enterocolitis; Prevent necrotizing enterocolitis in premature infants with birth weight =<1.5 kg
Regulatory Designation U.S. - Orphan Drug (Prevent necrotizing enterocolitis in premature infants with birth weight =<1.5 kg)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/13/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today